Form 4: Director Bridget Ross Acquires LMAT Stock, Options

LEMAITRE VASCULAR Director Bridget Ross reported the acquisition of 533 common shares as restricted stock units and 3,431 stock options.

Summary

• Bridget A Ross, a Director of LEMAITRE VASCULAR INC (LMAT), acquired 533 shares of common stock on December 10, 2025, as a restricted stock unit (RSU) award.
• The RSU award vests on a time-based schedule: 33 1/3% vests on December 1, 2026, with the remaining balance vesting in equal annual installments over the subsequent two years.
• Following this transaction, Bridget A Ross beneficially owns 3,455 shares of common stock directly.
• Additionally, Bridget A Ross acquired 3,431 stock options on December 10, 2025, with an exercise price of $83.66 per share.
• These stock options are exercisable and vest over a three-year period, with 33 1/3% vesting on the first anniversary of December 1, 2025, and the balance vesting in equal annual installments over the remaining two years.
• The stock options have an expiration date of December 10, 2030.
• Following this transaction, Bridget A Ross beneficially owns 3,431 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The acquisition of shares and options by a director, even as compensation, is generally viewed as a positive signal, indicating alignment of interests and potential confidence in the company's future. The vesting schedule encourages long-term commitment.

Positives

• A director's acquisition of company stock and options, even as compensation, generally signals confidence in the company's future performance and aligns management interests with shareholders.
• The vesting schedules for both the restricted stock units and stock options incentivize long-term commitment and performance from the director.

Future Outlook

The vesting schedules for the restricted stock units and stock options indicate a future increase in the director's beneficial ownership of common stock, contingent on continued service and company performance over the next three years.

Industry Context

This Form 4 filing reflects a routine insider compensation event within the medical device industry, where equity awards are a common component of executive and director remuneration to align interests with long-term company success.

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with shareholder value through equity ownership and performance-based vesting.
• Employees: May signal stability and confidence in leadership, potentially boosting morale.

Next Steps

• Vesting of 33 1/3% of restricted stock units on December 1, 2026, with subsequent annual installments.
• Vesting of 33 1/3% of stock options on December 1, 2026 (first anniversary of exercisable date), with subsequent annual installments.

Key Dates

Recommendation

While the director's acquisition of equity awards is a positive signal of alignment and confidence, a single Form 4 filing, particularly for compensation, typically does not warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position, suggesting continued monitoring of the company's performance and broader market conditions.

Keywords

LEMAITRE VASCULAR, LMAT, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Director Compensation, Beneficial Ownership